Abstract:Abstract Chimeric antigen receptor (CAR) NK and T cell therapy are promising immunotherapeutic approaches for the treatment of cancer. However, the efficacy of CAR NK/T cell therapy is often hindered by various factors, including the phenomenon of trogocytosis, which involves the bidirectional exchange of membrane fragments between cells. In this review, we explore the role of trogocytosis in CAR NK/T cell therapy and highlight potential strategies for its modulation to improve therapeutic efficacy. We provide an in-depth analysis of trogocytosis as it relates to the fate and function of NK and T cells, focusing on its effects on cell activation, cytotoxicity, and antigen presentation. We discuss how trogocytosis can mediate transient antigen loss on cancer cells, thereby negatively affecting the effector function of CAR NK/T cells. Additionally, we address the phenomenon of fratricide and trogocytosis-associated exhaustion, which can limit the persistence and effectiveness of CAR-expressing cells. Furthermore, we explore how trogocytosis can impact CAR NK/T cell functionality, including the acquisition of target molecules and the modulation of signaling pathways. To overcome the negative effects of trogocytosis on cellular immunotherapy, we propose innovative approaches to modulate trogocytosis and augment CAR NK/T cell therapy. These strategies encompass targeting trogocytosis-related molecules, engineering CAR NK/T cells to resist trogocytosis-induced exhaustion and leveraging trogocytosis to enhance the function of CAR-expressing cells. By overcoming the limitations imposed by trogocytosis, it may be possible to unleash the full potential of CAR NK/T therapy against cancer. The knowledge and strategies presented in this review will guide future research and development, leading to improved therapeutic outcomes in the field of immunotherapy.

Trogocytosis in CAR immune cell therapy: a key mechanism of tumor immune escape

Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape

Outsmarting trogocytosis to boost CAR NK/T cell therapy

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape

Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Resistance and recurrence of malignancies after CAR-T cell therapy

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Mechanisms of resistance to CAR T cell therapies

Low-affinity CAR T cells exhibit reduced trogocytosis, preventing fratricide and antigen-negative tumor escape while preserving anti-tumor activity

Clinical Status, Drug Resistance, and Countermeasures of CAR-T Cell Cancer Immunotherapy

Strategies for Dodging the Obstacles in CAR T Cell Therapy

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Cathepsin B causes trogocytosis-mediated CAR T cell dysfunction

Current state of CAR-T therapy for T-cell malignancies

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy